Author: Steve Fifield 3rd March 2026

I wrote a simple draft paper on possible reasons why ME/CFS and similar conditions struggle so much for public recognition and funding.

Executive Summary

This briefing paper proposes that illnesses characterised by gradual onset, symptom invisibility, and ambiguous loss—such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)—face structural disadvantages in public recognition and research funding.

In contrast to diseases associated with sudden, catastrophic diagnoses (e.g., cancer, motor neurone disease, multiple sclerosis), ME/CFS often progresses gradually, without a singular crisis moment that mobilises families, media, and policymakers.

Drawing on psychological research, communication theory, medical sociology, and health policy analysis, this paper outlines evidence supporting the hypothesis that acute grief catalyses mobilisation, while chronic ambiguity fosters adaptation rather than advocacy.

1. Proposition Statement

Public support for disease research funding is strongly influenced by emotional salience, narrative clarity, and visibility.

• This paper proposes that:
• Sudden, high-intensity diagnoses generate collective grief and advocacy mobilisation.
• Gradual, invisible illness trajectories tend to produce adaptation and normalisation rather than public outrage.
• Conditions lacking clear biomarkers or dramatic ‘trigger events’ may remain socially marginalised and underfunded.

2. Psychological Evidence: Emotion, Grief, and Giving

Research in behavioural psychology demonstrates that emotional intensity significantly influences charitable giving and advocacy behaviour.

• Key evidence includes:
• The ‘Identifiable Victim Effect’ shows individuals donate more readily when harm is concrete and personal (Small & Loewenstein, 2003).
• Personal experience with illness strongly predicts sustained advocacy engagement (Bekkers & Wiepking, 2011).
• Acute grief produces action-oriented coping responses, whereas ambiguous loss can lead to prolonged emotional adjustment rather than mobilisation (Boss, 1999).

3. Media Visibility and Agenda Setting

Agenda-setting research demonstrates that media coverage shapes public perceptions of issue importance (McCombs & Shaw, 1972).

• Relevant dynamics:
• Diseases with dramatic diagnostic narratives are more likely to receive concentrated media attention.
• High-visibility campaigns (e.g., viral fundraising movements) significantly increase funding inflows.
• Invisible or contested illnesses struggle to achieve sustained media framing as urgent biomedical crises.

4. Medical Sociology: Invisible and Contested Illness

ME/CFS has historically been classified as a contested or medically unexplained illness.

• Sociological findings show:
• Illnesses lacking objective biomarkers often face legitimacy challenges (Barker, 2008).
• Symptom invisibility contributes to stigma and disbelief (Dickson et al., 2007).
• Gradual functional decline may be socially normalised within families, reducing collective mobilisation.

5. Research Funding and Disease Burden

Multiple analyses indicate that biomedical research funding does not consistently align with disease burden.

• Findings relevant to ME/CFS:
• Funding levels for ME/CFS have historically been substantially lower than expected based on disability-adjusted life years (DALYs) (Dimmock et al., 2016).
• Mortality salience and media visibility correlate more strongly with funding allocation than chronic disability alone.
• Conditions perceived as life-threatening often secure greater political and philanthropic urgency.

6. Policy and Strategic Implications

If this proposition is valid, important implications follow for research institutions, advocacy organisations, and policymakers.

• Potential strategies:
• Develop narrative frameworks that communicate cumulative functional loss without sensationalism.
• Align funding mechanisms more closely with disease burden metrics rather than media salience.
• Invest in biomarker research to strengthen clinical legitimacy.
• Promote public education campaigns that clarify the biological basis and severity of ME/CFS.

Conclusion

ME/CFS exemplifies how gradual-onset, invisible illnesses may be structurally disadvantaged within public funding ecosystems shaped by emotion, visibility, and narrative shock.

Addressing this imbalance requires deliberate policy design, improved public communication, and recognition that chronic disability without dramatic rupture can be equally life-altering.

Selected References

1. Barker, K. (2008). Electronic support groups, patient-consumers, and medicalization.
2. Bekkers, R., & Wiepking, P. (2011). A literature review of empirical studies of philanthropy.
3. Boss, P. (1999). Ambiguous Loss: Learning to Live with Unresolved Grief.
4. Dickson, A., et al. (2007). Stigma in chronic fatigue syndrome.
5. Dimmock, M., et al. (2016). Estimating the disease burden of ME/CFS in the United States.
6. McCombs, M., & Shaw, D. (1972). The agenda-setting function of mass media.
7. Small, D., & Loewenstein, G. (2003). Helping a victim or helping the victim: Identifiable victim effect.